Sign inGet started

BRVE

Braveheart Bio, Inc.CIK 2131524 ☆ Sign in to watchCongress trades
Open-mkt buys · 90d
$318.07M
26 trades · 12 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$318.07M
Insiders on file
15

AI insights for BRVE PRO

XXXX$█.██M██+██%
XXXX$█.██M██+██%
XXXX$█.██M██+██%
XXXX$█.██M██+██%
XXXX$█.██M██+██%
AI insights for BRVE
Insider sentiment score with a plain-English explanation, conviction score on every buy, and how the stock performed 30 and 90 days after past insider buys.
Upgrade to Pro · $99/yearAlready Pro? Log in

Daily buy vs sell · 90 days

$318.07M2026-08-07 buys $318.07M 2026-08-07 sales —08-07
■ Open-market buys (P)   ■ Open-market sales (S) · daily dollar value by transaction date

Insiders

InsiderRoleTradesBoughtSoldLast trade
Anderson Michele A.Chief Development Officer4$40.0K$02026-08-07
Malek David IDirector4$150.0K$02026-08-07
Jiangsu Hengrui Pharmaceuticals Co., Ltd.10% Owner4$0$02026-08-07
Forbion Growth Opportunities Fund III Cooperatief U.A.10% Owner12$129.60M$02026-08-07
AH Bio Fund IV, L.P.10% Owner3$19.80M$02026-08-07
Murdoch TravisCEO and President, Director4$3.00M$02026-08-07
OrbiMed Genesis GP LLCDirector, 10% Owner4$34.92M$02026-08-07
Viehbacher ChristopherDirector4$3.00M$02026-08-07
Chimovits ErezDirector, 10% Owner10$69.84M$02026-08-07
Rickey James PaulChief Financial Officer4$1000.0K$02026-08-07
Lubner David CharlesDirector4$2.00M$02026-08-07
Andreessen Marc L10% Owner3$19.80M$02026-08-07
ORBIMED ADVISORS LLCDirector, 10% Owner4$34.92M$02026-08-07
Lohoff TimDirector2$0$02026-08-05
Bos JasperDirector2$0$02026-08-05

Trade history

InsiderRoleCodeTradeFiledSharesPriceValueOwned after
Forbion Growth Opportunities F10% Owner C Conversion deriv2026-08-072026-08-0735,000,000— $00SEC↗
Forbion Growth Opportunities F10% Owner C Conversion deriv2026-08-072026-08-0740,000,000— $00SEC↗
Jiangsu Hengrui Pharmaceutical10% Owner C Conversion deriv2026-08-072026-08-1032,500,000— $00SEC↗
OrbiMed Genesis GP LLCDirector, 10% Owner C Conversion deriv2026-08-072026-08-1140,000,000— $00SEC↗
Chimovits ErezDirector, 10% Owner C Conversion deriv2026-08-072026-08-1140,000,000— $00SEC↗
Andreessen Marc L10% Owner C Conversion deriv2026-08-072026-08-1140,000,000— $00SEC↗
Lubner David CharlesDirector P Buy2026-08-072026-08-0755,555$18.00 $1000.0K55,555SEC↗
Murdoch TravisCEO and President P Buy2026-08-072026-08-0783,333$18.00 $1.50M2,940,670SEC↗
Anderson Michele A.Chief Development Officer P Buy2026-08-072026-08-071,111$18.00 $20.0K332,161SEC↗
Malek David IDirector P Buy2026-08-072026-08-074,166$18.00 $75.0K533,845SEC↗
Viehbacher ChristopherDirector P Buy2026-08-072026-08-0783,333$18.00 $1.50M609,519SEC↗
Rickey James PaulChief Financial Officer P Buy2026-08-072026-08-0727,777$18.00 $500.0K520,927SEC↗
Forbion Growth Opportunities F10% Owner C Conversion2026-08-072026-08-077,990,867— $08,505,478SEC↗
Forbion Growth Opportunities F10% Owner P Buy2026-08-072026-08-071,920,000$18.00 $34.56M11,640,546SEC↗
Forbion Growth Opportunities F10% Owner P Buy2026-08-072026-08-071,680,000$18.00 $30.24M10,185,478SEC↗
Forbion Growth Opportunities F10% Owner C Conversion2026-08-072026-08-079,132,420— $09,720,546SEC↗
Jiangsu Hengrui Pharmaceutical10% Owner C Conversion2026-08-072026-08-107,420,091— $07,420,091SEC↗
OrbiMed Genesis GP LLCDirector, 10% Owner P Buy2026-08-072026-08-11273,333$18.00 $4.92M273,333SEC↗
OrbiMed Genesis GP LLCDirector, 10% Owner C Conversion2026-08-072026-08-119,132,420— $010,235,159SEC↗
OrbiMed Genesis GP LLCDirector, 10% Owner P Buy2026-08-072026-08-111,666,667$18.00 $30.00M11,901,826SEC↗
Chimovits ErezDirector, 10% Owner P Buy2026-08-072026-08-11273,333$18.00 $4.92M273,333SEC↗
Chimovits ErezDirector, 10% Owner P Buy2026-08-072026-08-111,666,667$18.00 $30.00M11,901,826SEC↗
Chimovits ErezDirector, 10% Owner C Conversion2026-08-072026-08-119,132,420— $010,235,159SEC↗
Andreessen Marc L10% Owner C Conversion2026-08-072026-08-119,132,420— $09,132,420SEC↗
Andreessen Marc L10% Owner P Buy2026-08-072026-08-111,100,000$18.00 $19.80M10,232,420SEC↗
Rickey James PaulChief Financial Officer P Buy2026-08-072026-08-0727,777$18.00 $500.0K520,927SEC↗
Viehbacher ChristopherDirector P Buy2026-08-072026-08-0783,333$18.00 $1.50M609,519SEC↗
Malek David IDirector P Buy2026-08-072026-08-074,166$18.00 $75.0K533,845SEC↗
Murdoch TravisCEO and President, Director P Buy2026-08-072026-08-0783,333$18.00 $1.50M2,940,670SEC↗
Lubner David CharlesDirector P Buy2026-08-072026-08-0755,555$18.00 $1000.0K55,555SEC↗
Forbion Growth Opportunities F10% Owner C Conversion deriv2026-08-072026-08-0735,000,000— $00SEC↗
Forbion Growth Opportunities F10% Owner C Conversion deriv2026-08-072026-08-0740,000,000— $00SEC↗
Forbion Growth Opportunities F10% Owner P Buy2026-08-072026-08-071,680,000$18.00 $30.24M10,185,478SEC↗
Forbion Growth Opportunities F10% Owner P Buy2026-08-072026-08-071,920,000$18.00 $34.56M11,640,546SEC↗
Forbion Growth Opportunities F10% Owner C Conversion2026-08-072026-08-077,990,867— $08,505,478SEC↗
Forbion Growth Opportunities F10% Owner C Conversion2026-08-072026-08-079,132,420— $09,720,546SEC↗
Anderson Michele A.Chief Development Officer P Buy2026-08-072026-08-071,111$18.00 $20.0K332,161SEC↗
Jiangsu Hengrui Pharmaceutical10% Owner C Conversion deriv2026-08-072026-08-1032,500,000— $00SEC↗
Jiangsu Hengrui Pharmaceutical10% Owner C Conversion2026-08-072026-08-107,420,091— —7,420,091SEC↗
Chimovits ErezDirector, 10% Owner C Conversion deriv2026-08-072026-08-1140,000,000— $00SEC↗
Chimovits ErezDirector, 10% Owner P Buy2026-08-072026-08-11273,333$18.00 $4.92M273,333SEC↗
Chimovits ErezDirector, 10% Owner P Buy2026-08-072026-08-111,666,667$18.00 $30.00M11,901,826SEC↗
Chimovits ErezDirector, 10% Owner C Conversion2026-08-072026-08-119,132,420— —10,235,159SEC↗
ORBIMED ADVISORS LLCDirector, 10% Owner C Conversion deriv2026-08-072026-08-1140,000,000— $00SEC↗
ORBIMED ADVISORS LLCDirector, 10% Owner P Buy2026-08-072026-08-11273,333$18.00 $4.92M273,333SEC↗
ORBIMED ADVISORS LLCDirector, 10% Owner P Buy2026-08-072026-08-111,666,667$18.00 $30.00M11,901,826SEC↗
ORBIMED ADVISORS LLCDirector, 10% Owner C Conversion2026-08-072026-08-119,132,420— —10,235,159SEC↗
AH Bio Fund IV, L.P.10% Owner C Conversion deriv2026-08-072026-08-1140,000,000— $00SEC↗
AH Bio Fund IV, L.P.10% Owner P Buy2026-08-072026-08-111,100,000$18.00 $19.80M10,232,420SEC↗
AH Bio Fund IV, L.P.10% Owner C Conversion2026-08-072026-08-119,132,420— —9,132,420SEC↗
Lubner David CharlesDirector A Award deriv2026-08-052026-08-0760,000— $060,000SEC↗
Bos JasperDirector A Award deriv2026-08-052026-08-0730,000— $030,000SEC↗
Murdoch TravisCEO and President A Award deriv2026-08-052026-08-07550,000— $0550,000SEC↗
Anderson Michele A.Chief Development Officer A Award deriv2026-08-052026-08-07300,000— $0300,000SEC↗
Malek David IDirector A Award deriv2026-08-052026-08-0730,000— $030,000SEC↗
Viehbacher ChristopherDirector A Award deriv2026-08-052026-08-0730,000— $030,000SEC↗
Chimovits ErezDirector, 10% Owner A Award deriv2026-08-052026-08-0730,000— $030,000SEC↗
Lohoff TimDirector A Award deriv2026-08-052026-08-0730,000— $030,000SEC↗
Rickey James PaulChief Financial Officer A Award deriv2026-08-052026-08-07300,000— $0300,000SEC↗
Rickey James PaulChief Financial Officer A Award deriv2026-08-052026-08-07300,000— $0300,000SEC↗
Lohoff TimDirector A Award deriv2026-08-052026-08-0730,000— $030,000SEC↗
Chimovits ErezDirector, 10% Owner A Award deriv2026-08-052026-08-0730,000— $030,000SEC↗
Viehbacher ChristopherDirector A Award deriv2026-08-052026-08-0730,000— $030,000SEC↗
Malek David IDirector A Award deriv2026-08-052026-08-0730,000— $030,000SEC↗
Murdoch TravisCEO and President, Director A Award deriv2026-08-052026-08-07550,000— $0550,000SEC↗
Lubner David CharlesDirector A Award deriv2026-08-052026-08-0760,000— $060,000SEC↗
Bos JasperDirector A Award deriv2026-08-052026-08-0730,000— $030,000SEC↗
Anderson Michele A.Chief Development Officer A Award deriv2026-08-052026-08-07300,000— $0300,000SEC↗